Elena Chertova

Summary

Country: USA

Publications

  1. pmc Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions
    Nathan C Gaddis
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Virol 77:5810-20. 2003
  2. pmc Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus
    Elena Chertova
    AIDS Vaccine Program, SAIC Frederick, Maryland 21702 1201, USA
    J Virol 76:5315-25. 2002
  3. pmc Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages
    Elena Chertova
    AIDS Vaccine Research Program, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    J Virol 80:9039-52. 2006
  4. pmc Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1
    Lori V Coren
    AIDS Vaccine Program, SAIC Frederick, Inc, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    J Virol 81:10047-54. 2007
  5. pmc The Mamu B 17-restricted SIV Nef IW9 to TW9 mutation abrogates correct epitope processing and presentation without loss of replicative fitness
    Jacob T Minang
    AIDS and Cancer Virus Program, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
    Virology 375:307-14. 2008
  6. ncbi request reprint Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins
    Elena Chertova
    AIDS Vaccine Program, SAIC Frederick, National Cancer Institute at Frederick, Building 535, Fifth Floor, Frederick, MD 21702, USA
    Curr Mol Med 3:265-72. 2003
  7. pmc Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles
    Charles M Trubey
    Basic Research Program Research Technology Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, Maryland 21702 1201, USA
    J Virol 77:12699-709. 2003
  8. pmc Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies
    Gregory Q Del Prete
    AIDS and Cancer Virus Program, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
    J Virol 87:4584-95. 2013
  9. ncbi request reprint Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins
    Jeffrey D Lifson
    AIDS Vaccine Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    AIDS Res Hum Retroviruses 20:772-87. 2004
  10. ncbi request reprint HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensi
    Mark K Louder
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Virology 339:226-38. 2005

Collaborators

Detail Information

Publications16

  1. pmc Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions
    Nathan C Gaddis
    Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Virol 77:5810-20. 2003
    ..Based on the inability of this comprehensive analysis to uncover molecular defects in Delta vif virions, we speculate that such defects are likely to be subtle and/or rare...
  2. pmc Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus
    Elena Chertova
    AIDS Vaccine Program, SAIC Frederick, Maryland 21702 1201, USA
    J Virol 76:5315-25. 2002
    ..These findings suggest that incorporation of SU-TM complexes into the viral membrane may be the primary factor determining the quantity of SU associated with SIV and HIV-1 virions, rather than shedding of SU from mature virions...
  3. pmc Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages
    Elena Chertova
    AIDS Vaccine Research Program, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    J Virol 80:9039-52. 2006
    ..MDM-derived HIV contained 26 of 37 proteins previously found in exosomes, consistent with the idea that HIV uses the late endosome/multivesicular body pathway during virion budding from macrophages...
  4. pmc Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1
    Lori V Coren
    AIDS Vaccine Program, SAIC Frederick, Inc, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    J Virol 81:10047-54. 2007
    ..In turn, this finding suggests an important role for the p9(NC/SP2) species in some aspect of integration...
  5. pmc The Mamu B 17-restricted SIV Nef IW9 to TW9 mutation abrogates correct epitope processing and presentation without loss of replicative fitness
    Jacob T Minang
    AIDS and Cancer Virus Program, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
    Virology 375:307-14. 2008
    ..Our data highlight the value of functional assays using virus-infected target cells as opposed to peptide-pulsed APC when assessing relevant escape mutations in CTL epitopes...
  6. ncbi request reprint Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins
    Elena Chertova
    AIDS Vaccine Program, SAIC Frederick, National Cancer Institute at Frederick, Building 535, Fifth Floor, Frederick, MD 21702, USA
    Curr Mol Med 3:265-72. 2003
    ..The results indicate that as judged by both biochemical and biological (infectivity) criteria, inactivation by AT-2 does not appear to be reversible under conditions likely to obtain in vivo...
  7. pmc Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles
    Charles M Trubey
    Basic Research Program Research Technology Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, Maryland 21702 1201, USA
    J Virol 77:12699-709. 2003
    ..Our observations demonstrate the utility of CD45 immunoaffinity-based approaches for producing highly purified retrovirus preparations for applications that would benefit from the use of virus that is essentially free of microvesicles...
  8. pmc Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies
    Gregory Q Del Prete
    AIDS and Cancer Virus Program, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
    J Virol 87:4584-95. 2013
    ..These analyses suggest that there may be underappreciated features of SIV in vivo challenge stocks with the potential to impact early infection events, which may merit consideration when selecting virus stocks for in vivo studies...
  9. ncbi request reprint Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins
    Jeffrey D Lifson
    AIDS Vaccine Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    AIDS Res Hum Retroviruses 20:772-87. 2004
    ..With further optimization, AT-2-inactivated viral particles may be a useful class of immunogen in the development of a vaccine to prevent AIDS...
  10. ncbi request reprint HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensi
    Mark K Louder
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Virology 339:226-38. 2005
    ..Replication competent HIV-1 and isogenic envelope pseudoviruses have similar neutralization characteristics, but passage into PBMC is associated with decreased sensitivity to neutralization...
  11. ncbi request reprint Distribution and three-dimensional structure of AIDS virus envelope spikes
    Ping Zhu
    Department of Biological Science and Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida 32306, USA
    Nature 441:847-52. 2006
    ..Reconciling available atomic structures with the three-dimensional whole spike density map yields insights into the orientation of Env spike structural elements and possible structural bases of their functions...
  12. pmc HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease
    Abdul A Waheed
    Virus Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:8467-71. 2007
    ..These data reveal that HIV-1 can escape from an inhibitor of viral entry by acquiring mutations that cause the cytoplasmic tail of gp41 to be cleaved by the viral protease...
  13. pmc Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions
    Ping Zhu
    Department of Biological Science and Institute of Molecular Biophysics, Florida State University, Tallahassee, FL 32306, USA
    Proc Natl Acad Sci U S A 100:15812-7. 2003
    ....
  14. ncbi request reprint Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions
    Hongzhan Xu
    Viral Mutation Section, HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute Frederick, P O Box B, Bldg 535, Rm 334, Frederick, MD 21702, USA
    Virology 360:247-56. 2007
    ..These results indicate that virion incorporation of only a few molecules of A3G is sufficient to inhibit HIV-1 replication...
  15. pmc Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts
    David R M Graham
    The Leukocyte Immunochemistry Laboratory, Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Virol 77:8237-48. 2003
    ....
  16. pmc Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope
    Yossef Raviv
    Center for Cancer Research Nanobiology Program, NCI Frederick, Frederick, MD 21702, USA
    J Virol 79:12394-400. 2005
    ..Targeting the lipid domain of biological membranes with hydrophobic alkylating compounds could be used as a general approach for inactivation of enveloped viruses and other pathogenic microorganisms for vaccine application...